Skip to main content
Premium Trial:

Request an Annual Quote

Oncocyte, Guardian Research Network Partner to Improve Precision Medicine Clinical Trials

NEW YORK – Molecular diagnostics company Oncocyte and hospital consortium Guardian Research Network (GRN said on Thursday that they've formed a strategic collaboration aimed at improving precision medicine clinical trials, with an initial focus on immuno-oncology 


The partners said they plan to create a comprehensive solution for pharmaceutical clients that will encompass everything from patient recruitment to regulatory approvals. GRN will contribute its clinical trial enrollment and data science technology while Oncocyte will add its proprietary molecular tests — including DetermaRx for early-stage lung cancer and DetermaIO for immunotherapy selection — as well as its pharma and companion diagnostic development services.  


The collaboration is designed to reduce the time it takes to populate immune targeting trials while also improving chances for successful trials through proprietary molecular patient stratification, the partners said. 


"Our alliance with GRN may help us to expand our pharma services offerings and increase DetermaIO's use in more clinical trials for immune therapy patient selection," Oncocyte President and CEO Ron Andrews said in a statement. "This collaboration with GRN enables us to help streamline clinical trial enrollment for pharmaceutical company sponsors and ideally positions us to provide comprehensive services needed by emerging biopharma companies that are developing new immune-oncology and targeted therapies."

The Scan

Study Reveals New Details About Genetics of Major Cause of Female Infertility

Researchers in Nature Medicine conducted a whole-exome sequencing study of mote than a thousand patients with premature ovarian insufficiency.

Circulating Tumor DNA Shows Potential as Biomarker in Rare Childhood Cancer

A study in the Journal of Clinical Oncology has found that circulating tumor DNA levels in rhabdomyosarcoma may serve as a biomarker for prognosis.

Study Recommends Cancer Screening for Dogs Beginning Age Seven, Depending on Breed

PetDx researchers report in PLOS One that annual cancer screening for dogs should begin by age seven.

White-Tailed Deer Harbor SARS-CoV-2 Variants No Longer Infecting Humans, Study Finds

A new study in PNAS has found that white-tailed deer could act as a reservoir of SARS-CoV-2 variants no longer found among humans.